Lincoln Educational Services (LINC) Tops Q2 EPS by 2c; Guides Q3, FY12 Below Views
Get Alerts LINC Hot Sheet
Price: $25.37 -0.12%
Revenue Growth %: +7.8%
Financial Fact:
Selling, general and administrative: 24.36M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +7.8%
Financial Fact:
Selling, general and administrative: 24.36M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Lincoln Educational Services (NASDAQ: LINC) reported Q2 EPS of ($0.14), $0.02 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $100.4 million versus the consensus estimate of $101.76 million.
Lincoln Educational Services sees Q3 2012 EPS of $-0.50-$-0.45, versus the consensus of $0.12. Lincoln Educational Services sees Q3 2012 revenue of $102-$104 million, versus the consensus of $113.20 million.
Lincoln Educational Services sees FY2012 EPS of $-1.30-$-1.24, versus the consensus of $0.19. Lincoln Educational Services sees FY2012 revenue of $420-$430 million, versus the consensus of $435.0 million.
For earnings history and earnings-related data on Lincoln Educational Services (LINC) click here.
Lincoln Educational Services sees Q3 2012 EPS of $-0.50-$-0.45, versus the consensus of $0.12. Lincoln Educational Services sees Q3 2012 revenue of $102-$104 million, versus the consensus of $113.20 million.
Lincoln Educational Services sees FY2012 EPS of $-1.30-$-1.24, versus the consensus of $0.19. Lincoln Educational Services sees FY2012 revenue of $420-$430 million, versus the consensus of $435.0 million.
For earnings history and earnings-related data on Lincoln Educational Services (LINC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Amneal gets FDA approval for lanreotide injection, launches immediately
- Corpay agrees to $100M FTC settlement over marketing practices
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share